AXSM
Axsome Therapeutics, Inc.
Stock
$179.25−2.82 (−1.55%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $777M | $638M | $386M | $271M | $50M |
| R&D | $188M | $183M | $187M | $98M | $58M |
| SG&A | $713M | $571M | $411M | $323M | $159M |
| Operating income | −$186M | −$167M | −$281M | −$232M | −$180M |
| Non-operating income | −$5.0M | −$17M | −$6.6M | −$6.5M | −$7.3M |
| Pretax income | −$191M | −$184M | −$287M | −$238M | −$187M |
| Taxes | $558K | −$530K | $85K | $960K | $0 |
| Net income | −$192M | −$183M | −$287M | −$239M | −$187M |
| Diluted EPS | −$3.75 | −$3.68 | −$5.99 | −$5.27 | −$4.60 |
| Diluted shares | — | 49.7M | 47.9M | 45.4M | 40.7M |
| Revenue growth | — | +65.5% | +42.5% | +440.8% | — |
| Operating margin | −24.0% | −26.1% | −72.7% | −85.7% | −359.3% |
| Net margin | −24.7% | −28.7% | −74.5% | −88.4% | −374.0% |